Kailera Therapeutics Inc KLRA
$16.23 $0.49 (3.11%) 1D
Last Updated: Sep 04, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Kailera Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of KLRA Stock
United States Health Care Mid Cap No. As of September 2026, Kailera Therapeutics Inc (KLRA) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Kailera Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. The company is headquartered in Waltham, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2026-04-17. The firm is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The firm is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.
KLRA Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Kailera Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Kailera Therapeutics Inc (KLRA) Chart
Financial Metrics & Statements of Kailera Therapeutics Inc (KLRA)
FAQ's for Kailera Therapeutics Inc (KLRA)
- As of September 2026, Kailera Therapeutics Inc KLRA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kailera Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kailera Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kailera Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kailera Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kailera Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Kailera Therapeutics Inc (KLRA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
